1. Pink Sheet
  2. >>Regulatory Trackers
  3. >>US FDA Performance Tracker

A Break-Even Year For US FDA Advisory Committees?

 
• By Michael McCaughan

Meetings have continued to be sparse through 2021, but there will end up being nearly as many panels on withdrawing approved uses as on approving new ones.

The ledger of approval vs withdrawal advisory committees will likely be in the black for the year, but it will be close. • Source: Alamy

When the US Food & Drug Administration’s Antimicrobial Drugs Advisory Committee met 7 October to review Takeda Pharmaceutical Co. Ltd.’s antiviral maribavir, it was just the tenth time the agency has convened a panel to review a pending new drug application in 2021.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from US FDA Performance Tracker

More from Regulatory Trackers